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Accepted 28 December 2010AbstractObjective: Conventional, intermittent, epidural morphine is widely applied as a post-Cesarean delivery analgesia. We compared the analgesic
efficacy, motor weakness, and side effects of administering a patient-controlled epidural analgesia (PCEA) of pure ropivacaine versus the
intermittent administration of epidural morphine after Cesarean delivery.
Materials and Methods: This randomized, double-blind study included 120 full-term parturients who underwent elective Cesarean delivery and
received either PCEA with pure ropivacaine or an intermittent bolus epidural of 2 mg/10 mL morphine in normal saline twice per day. The
efficacy of pain relief, post-Cesarean side effects, motor blockades, time to first ambulation, and global satisfaction scores were evaluated.
Results: Pain scores were recorded at the four evaluation times (2, 12, 24, and 48 hours post-Cesarean delivery), and the time to first ambulation
did not statistically differ between the two groups. Patients in the ropivacaine group experienced more motor weakness at 2 and 12 hours, fewer
side effects, and higher global satisfaction scores than those in the morphine group ( p < 0.05).
Conclusion: The analgesic efficacy after cesarean delivery was almost equivalent between two groups. PCEA with pure ropivacaine induced
significant motor blockade during the first 12 hours, but without delaying the time to first ambulation. Patients in the ropivacaine group reported
higher patient satisfaction scores due to the significant reduction of annoying side effects, such as pruritus, nausea, vomiting, and urinary
retention.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Many studies have shown that the use of opioids or local
anesthetics as an epidural analgesia, either alone or in
combination, provides superior pain control compared with
intravenous opioids after abdominal and thoracic surgical
procedures [1e3]. The use of morphine (2e3 mg, twice per
day) as an epidural analgesia after cesarean delivery is supe-
rior to other techniques, such as the intramuscular or intra-
venous administration of opioids, because it provides better* Corresponding author. Mao-Hsien Wang, MD, Department of Anesthesi-
ology, En-Chu-Kon Hospital, Taipei, Taiwan.
E-mail address: clk0619@ntu.edu.tw (M.-H. Wang).
1028-4559/$ - see front matter Copyright  2011, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2011.10.008and longer-lasting analgesic effects with fewer sensory, motor,
or sympathetic side effects [4,5]. Considering the high inci-
dence of annoying side effects that are induced by epidural
morphine, such as nausea, vomiting, pruritus, and urinary
retention, some patients are dissatisfied with epidural
morphine after cesarean delivery [6,7]. In the past few years,
some prophylactic methods have been developed to reduce or
prevent the incidence of side the effects induced by morphine
[8,9]. Furthermore, some reports have advocated using
a modified regimen, such as different combinations of local
anesthetics with opioids, to decrease opioid dosage and, thus,
reduce the incidence of annoying side effects. However, the
incidence of these side effects, such as pruritus, nausea,
vomiting, and urinary retention, may or may not be related tocs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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mens that contain even small doses of opioids still cause those
side effects, which are clinically bothersome to many patients.
While patient-controlled epidural analgesia (PCEA) with
local anesthetics alone provides good analgesic effects, it
causes motor weakness that inevitably limits postoperative
mobilization [12]. Ropivacaine produces less effects to the
central nervous system, cardiac toxicity, and motor blockades
and provides equivalent onset time, duration, and quality of
analgesia compared with bupivacaine [13e15]. Buggy et al
compared PCEA with ropivacaine alone and ropivacaine in
combination with fentanyl for post-Cesarean-delivery pain
relief and found a higher incidence of motor weakness after 8
hours [16]. However, their observation period was restricted to
the initial 24-hour postoperative period. Thus, the data
collected about analgesic efficacy, motor weakness, side
effects, and global satisfaction were incomplete due to the
limited observation period. Hypothesizing that these two
regimens should show equivalent analgesic efficacy post-
Cesarean delivery, we performed a prospective, randomized,
and double-blind study to compare the analgesic efficacy,
motor weakness, and side effects of PCEA with ropivacaine
versus intermittent bolus of epidural morphine for post-
Cesarean delivery analgesia.
Methods
After institutional review board approval and written
informed consent was obtained from each patient, the 120
patients (American Society of Anesthesiology [ASA] physical
status classification I or II; age range: 20e40 years), who were
scheduled to undergo elective Cesarean deliveries with
regional anesthesia, were randomized to receive either
epidural morphine analgesia or PCEAwith ropivacaine during
the postoperative 48-hour period. Randomization was
accomplished by randomly selecting sealed envelopes that
each contained one piece of paper with either “epidural
morphine” or “epidural ropivacaine” written on it. Patients
with a history of chronic pain, chronic opioid use, drug and/or
alcohol abuse, chronic headaches, backaches, or peripheral
neuropathy, and those who could not understand the use of
PCEA or the visual analogue scale (VAS) were excluded.
Baseline assessments of vital signs, including respiration rate,
pain score on a 10-cm VAS, motor functions based on
a modified Bromage scale, nausea, vomiting, and pruritus,
were recorded for every patient. After intravenous access had
been established and an infusion of crystalloid (0.9% sodium
chloride) had been administered, all patients underwent
combined spinal-epidural (CSE) anesthesia. Dural puncture
was performed using the needle-through-needle technique
with a Whitacre 26G needle. A local anesthetic (0.5% heavy
bupivacaine) was intrathecally injected before the epidural
catheter was inserted, and then the epidural catheter was
placed in the L4-5 or L3-4 interspace of each patient. A 3-mL
injection of 2% lidocaine was administrated through the
epidural catheter to test for intrathecal versus intravascular
placement. Spinal anesthesia was induced using 10e12 mgbupivacaine. No additional intravenous or epidural opioids or
epidural local anesthetics were administered during surgery.Postoperative analgesic techniques and assessmentBefore cesarean delivery, each patient drew a sealed
envelope and were then randomized into one of two groups
after delivery based on their selected envelope. The R group
(n ¼ 60) received 0.1% ropivacaine alone via PCEA (Provider
5500, Pancretec, ABBOTT Lab, USA) (5 mg bolus, 15 minute
lockout, with 3 mg/hour background infusion and a maximum
dose of 60 mg/4 hours) for 3 days [16]. The M group (n ¼ 60)
received 2 mg morphine in 10 mL normal saline epidurally
administered twice per day (8 AM and 8 PM) for 3 days. All
patients started their postoperative analgesic program imme-
diately after Cesarean delivery in the operating room. All of
the epidural catheters were attached to infusion pumps for
both therapeutic groups so that the observers (i.e., the nursing
staff) were blinded to the treatment groups. Inadequate anal-
gesia was defined as patients still feeling pain (VAS score
>40 mm) after receiving postoperative pain management.
Inadequate analgesia was managed by an intermittent, intra-
muscular injection of 25 mg meperidine. Nausea and vomiting
were managed by 0.5 mg droperidol that was intravenously
delivered. Hypotension was prevented by challenge with
500 mL of normal saline before spinal anesthesia, and was
treated with intermittent intravenous ephedrine. If a motor
blockade impaired ambulation, PCEAwas withheld for 1 hour
and the bolus dose was reduced to half of the previous dose. If
drowsiness or respiratory depression occurred, epidural
morphine was also reduced by half. The analgesic regimen
was prepared by the anesthesiologist managing the patient,
who was not involved in data collection, and was administered
in the recovery room while the spinal block was still effective.
Patients and nursing staff were blinded to the group random-
ization during data collection.
All patients were assessed using the 100-mm VAS while at
rest and when moving by nursing staff who were not involved
in the bedside patient care; side effects of the postoperative
analgesia were also assessed at four different evaluation times
(2, 12, 24, and 48 hours after the first bolus of ropivacaine or
morphine). The VAS pain scales consisted of 100-mm hori-
zontal lines drawn on a sheet of paper without any markings,
anchored with “no pain” at the left and “worst pain possible”
at the right. Nausea, vomiting, and pruritus were rated four
times in terms of incidence and severity over the postoperative
48-hr period using the following scoring system: 0, side effect
not experienced; 1, side effects experienced, no treatment
needed; 2, side effect experienced, treatment effective; 3, side
effect experienced, treatment ineffective [17]. Vomiting was
defined as an integrated reflex that results in forceful expulsion
of the stomach contents, including a nonproductive expulsion.
Nausea was defined as the sensation of wishing to vomit or
retch [18]. Pruritus was defined as the central type of itching
induced by epidural opioids, where the itching sensation
occurs only on the face or central part of the trunk, excluding
itching of the arms or legs.
Table 1
Patient demographic and clinical characteristics.
Ropivacaine group
(n ¼ 60)
Morphine group
(n ¼ 60)
Age (y) 29.3  5.8 28.8  6.3
Height (cm) 161.8  6.1 162.7  5.5
Weight (kg) 69.5  7.9 71.7  8.6
Parity: nulliparous/
multiparous (n)
24/36 26/34
Time of first ambulation
after delivery (h)
23.45  5.72 22.28  5.38
Patients who requested
supplementary aanalgesia
0 2
Values are the means  SD or number (n).
No differences were found between the two groups.
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respiratory rate, pulse rate, and noninvasive blood pressure
measurements) were measured and all of these data were
recorded every 6 hours on the first day and then every 12 hours
on the following day. The appearance of respiratory depression
(respiratory rate <8 breaths/minute) and hypotension (systolic
blood pressure [SBP] <90 mmHg or 20% below baseline
SBP) were also recorded. Sedation was assessed using a four-
point scale: 0, fully alert; 1, drowsy, eyes closed occasionally;
2, asleep but easily roused by speaking to the patient; 3,
profoundly sedated, roused by physical stimulation. The
occurrence of a motor block was evaluated using the modified
Bromage scale (0, no motor blockade; 1, able to flex hip and
knee but unable to perform a straight leg raise; 2, able to move
ankle only; 3, unable to move the lower limbs). Demonstrable
motor weakness was defined as Bromage grade 1 or higher and
was recorded by the nursing staff.
The time of first ambulation was recorded for each patient.
The criteria used to declare a patient capable of her first
ambulation were the following: stable vital signs for at least
1 hour; no sign of respiratory depression or airway obstruc-
tion; patient aware of time, place, and person; patient able to
walk and dress unaided; patient having bearable or little pain
during ambulation (VAS <30 mm).
The number of patients in each group who requested
supplementary analgesia (intermittent intramuscular injection of
25 mg meperidine) due to inadequate analgesia (VAS> 40 mm)
was recorded during the 48-hour evaluation period. All patients
reported their global satisfaction with the quality of their post-
Cesarean analgesia using a 5-point verbal rating scale (1, very
satisfied; 2, satisfied; 3, indifferent; 4, dissatisfied; 5, very
dissatisfied) on the day before hospital discharge [19]. The
normal hospital discharge is 5 days after delivery.Statistical analysisFig. 1. Comparisons of visual analog scale scores for pain that occurred at rest
or while moving for ropivacaine and morphine. Bars denote the means  SDs.
Scores did not differ significantly between the two groups.In this study, we recorded and compared the analgesic
efficacy as the primary outcome and side effects (e.g., nausea,
vomiting, pruritus, and drowsiness), motor blockade, time to
first ambulation, and global satisfaction scores were regarded
as secondary outcomes. We hypothesized that the analgesic
efficacies of the two pain management treatments would be
equivalent. A power analysis showed that 51 patients per
group would provide 80% of the power to detect a relative
difference of 20% in terms of the secondary outcomes between
the two groups.
Continuous variables (e.g., patient characteristics such as
maternal age, height, weight, etc.) were analyzed using
Student’s unpaired t-tests. Categorical data for each of the two
study groups (including incidence of side effects and the number
of patients requesting extra analgesia) were reported as numbers
and percentages and were analyzed using the chi-square test.
Nonparametric data (such as VAS pain scores at rest and while
moving at different evaluation times, global satisfaction scores,
and time of first ambulation) were reported as the means SDs
and were analyzed using the Kruskal-Wallis test. A value of
p < 0.05 was considered statistically significant.Results
There were no demographic differences between the ropi-
vacaine PCEA and epidural morphine groups (Table 1).
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not differ significantly between the two groups (Fig. 1). In the
morphine group, one patient was sleepy but was able to
respond to verbal commands. One patient in the ropivacaine
group became hypotensive. No respiratory depression or
tachyphylaxis occurred. Zero patients in the ropivacaine
group, but two patients in the morphine group, complained of
inadequate analgesia and requested supplementary pain relief;
however, the difference between the two groups was not
statistically significant (Table 1). The overall global satisfac-
tion of the ropivacaine group was greater than that of the
morphine group at each of the four evaluation times
( p < 0.05) (Fig. 2).
The incidence, mean severity score, and distribution of
motor weakness and side effects (e.g., nausea, vomiting, and
pruritus) are shown in Table 2. The incidence of side effects
(nausea, vomiting, and pruritus) were significantly higher in
the morphine group compared with the ropivacaine group at 2,
12, 24, and 48 hours after the first bolus was administered
( p < 0.05) (Table 2). The incidence of demonstrable motor
weakness (Bromage grade 1 or higher) was significantlyFig. 2. Comparisons of global satisfaction scores at (A) 2 hours, (B) 12 hours, (C) 2
morphine groups. Results are based on the satisfaction scale rating, where 1 is thehigher in the ropivacaine group than in the morphine group at
2 and 12 hours post-Cesarean delivery ( p < 0.05), but not at
24 or 48 hours postdelivery (Table 2).
The mean severity scores of the side effects (e.g., nausea,
vomiting, and pruritus) were significantly higher in the
morphine group at 2, 12, 24, and 48 hours after bolus
administration ( p < 0.05) (Table 2). The mean Bromage
motor weakness score was insignificantly higher in the ropi-
vacaine group compared with the morphine group at 2 and 12
hours post-Cesarean delivery ( p < 0.05), but not at 24 or 48
hours postdelivery (Table 2). For patients in the ropivacaine
group, the total ropivacaine consumption was 189  26 mg in
24 hours and 77  31 mg in 48 hours.
Discussion
Intravenous or epidural morphine following post-Cesarean
delivery has been used clinically in recent decades with
excellent analgesic effects, but it has bothersome side effects,
such as pruritus, nausea, and vomiting, which are difficult to
prevent [8,9,20]. Recently, patients have become dissatisfied4 hours, and (D) 48 hours post-Cesarean delivery between the ropivacaine and
most and 5 is the least satisfied.
Table 2
Incidence, severity score (mean), and distribution of reported motor weakness
and side effects in the ropivacaine and morphine groups.
Score (Mean) Ropivacaine
(n ¼ 60)
Score (Mean) Morphine
(n ¼ 60)
Degree of
severity
Degree of
severity
0 1 2 3 0 1 2 3
Nausea score (n)
2 h 0.57* 29# 28 3 0 1.23* 13# 20 27 1
12 h 0.51* 32# 25 3 0 1.18* 17# 16 26 1
24 h 0.38* 44# 9 7 0 0.75* 25# 16 18 1
48 h 0.18* 51# 7 2 0 0.41* 41# 13 6 0
Pruritus score (n)
2 h 0.08* 57# 2 1 0 1.47* 9# 15 35 1
12 h 0.05* 58# 1 1 0 1.43* 11# 13 35 1
24 h 0.03* 59# 0 1 0 0.78* 26# 22 11 1
48 h 0* 60# 0 0 0 0.6* 31# 22 7 0
Bromage grade (n)
2 h 0.91* 28# 16 9 7 0.3* 50# 4 4 2
12 h 0.47* 42# 10 6 2 0.1* 55# 4 1 0
24 h 0.05 57 3 0 0 0.02 59 1 0 0
48 h 0.02 59 1 0 0 0 60 0 0 0
*p < 0.05 for mean severity scores compared between the ropivacaine and
morphine groups.
#p < 0.05 for the incidence of motor weakness and side effects compared
between the ropivacaine and morphine groups.
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control [6,7]. The increasing use of combined spinal-epidural
anesthesia increases the possibility of the epidural adminis-
tration of a local anesthetic, such as bupivacaine, after spinal
anesthesia. Ropivacaine has motor-sparing effects and less
central nervous system and cardiac toxicity [15]; thus, PCEA
with ropivacaine has been suggested as superior to bupiva-
caine for postoperative pain control.
In 2000, Buggy et al showed that the incidence of
demonstrable motor weakness (Bromage grade 1 or higher)
was significantly higher in patients receiving PCEA ropiva-
caine at 8-hours postadministration, but not at 12 hours;
nevertheless, they did not evaluate the time of first ambulation
or global satisfaction [16]. Based on the methods used in their
assessment, could they conclude that the higher incidence of
motor weakness at 8 hours interfered with the time of first
ambulation and the quality of ambulation? Therefore, we
designed this prospective, randomized, and double-blind study
to evaluate the efficacy of pain relief, side effects (nausea,
vomiting, and pruritus), motor blockade, time of first ambu-
lation, and global satisfaction of PCEA with ropivacaine and
epidural morphine and, therefore, obtain useful clinical
information on post-Cesarean pain control. Among all of the
patients examined, no episode of significant vital sign insta-
bility was detected throughout the 48-hour, post-Cesarean
delivery period, except for one episode of sedation in the
morphine group (score > 1) and one episode of hypotension in
the ropivacaine group; however, both of these episodes were
transient. PCEA with a pure local anesthetic without the
addition of an opioid could result in tachyphylaxis, resulting inthe prolonged use of the local anesthetic, as has been reported
in previous studies [12,15]. In our study, no episode of
tachyphylaxis was detected in any patient throughout the 48-
hour, post-Cesarean delivery period.
The PCEA settings for the ropivacaine group (0.1% ropi-
vacaine, 5 mg bolus, 15 minute lockout with a 3 mg/hour
background infusion and a maximum dose of 60 mg/4 hours)
was the same as that used in the study by Buggy et al in 2000
because we believed that this setting provided an acceptable
balance between adequate analgesia and minimal occurrence
of motor blocking. Furthermore, Liu et al compared three
solutions of ropivacaine and fentanyl (1 mg/mL 0.05% ropi-
vacaine/fentanyl , 2 mg/mL 0.1% ropivacaine/fentanyl, and
4 mg/mL 0.2% ropivacaine/fentanyl ) as a postoperative
patient-controlled analgesia after lower abdominal surgery.
They found that higher concentrations of ropivacaine (0.2%)
induced a 30% incidence of motor block, but not in those
receiving lower concentrations of ropivacaine (0.05% or 0.1%)
[21]. Chaplan et al also demonstrated that the relative anal-
gesic potency of ropivacaine compared with bupivacaine was
about 0.6 and the EC50 for the minimum concentration of
ropivacaine administered during labor was approximately
0.16% [20]. Thus, 0.1% ropivacaine might not aggravate
motor weakness and be less likely to produce motor block than
0.1% bupivacaine.
From this prospective, randomized, and double-blind study,
our results demonstrate that PCEA with 0.1% ropivacaine
alone provides equivalent analgesic effects as epidural
morphine (2 mg administered twice per day) without delaying
the time to first ambulation, although the percentage of
demonstrable motor weakness was still significantly higher in
the ropivacaine group at 2 and 12 hours post-Cesarean
delivery. The reason why the time of first ambulation was
not delayed and motor blockade was insignificant after
12 hours between the two patient groups could be attributed to
the use of low-concentration ropivacaine (0.1%) in the PCEA
formula and because the duration of spinal anesthesia for all
patients was about 8e12 hours. Within the first 12 post-
operative hours, there could have been a synergistic effect
between spinal anesthesia and epidural analgesia in the ropi-
vacaine group. By significantly reducing the annoying side
effects (nausea, vomiting, and pruritus) and limiting the
influence on ambulation, patients reported higher global
satisfaction scores with PCEA than with ropivacaine. We
conclude that PCEA with 0.1 % ropivacaine alone provides
a better quality of pain relief than epidural morphine; thus, it is
a more efficient and acceptable analgesia for controlling pain
after a Cesarean delivery.
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